Navigation Links
Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up

Separate Survey Underscores Impact of Disease on Work Status and Productivity

WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ -- Findings presented today at Digestive Disease Week(R) 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE(R) (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.

The ACT extension trials were conducted in both the United States and Europe, under co-principle investigators William Sandborn, M.D. of the Mayo Clinic and Walter Reinisch, M.D., of the University Hospital Vienna, Austria. The data show that for patients who completed follow-up through week 56 of the extension trials, 92 percent reported mild or no disease activity, as measured by the Physician's Global Assessment (PGA). For patients followed through week 104, 97 percent reported mild or no disease activity.

At week 0 of the ACT extension trials, 76 percent of 229 responder patients enrolled had mild or no disease activity, as indicated by a PGA score of 0 or 1, and 41 percent had no disease activity (PGA score of 0). At week 56, 92 percent of those patients remaining in the extension trials (n=181) had mild or no disease activity, and 61 percent had no disease activity. At week 104, 97 percent of those patients remaining in the extension trials (n=97) had mild or no disease activity, and 75 percent had no disease activity.

"The data demonstrate the sustained efficacy of REMICADE for many patients with UC," said co-principle investigator Dr. Reinisch. "Because UC is a chronic condition, many patients live with cycles of recurring flares. This can greatly hinder a person's social and professional life. The availability of therapies that quickly reduce symptoms and maintain response and remissi on long term is a significant benefit to patients."

Separate data also presented at DDW today show the significant impact of UC on patients' productivity, employment and social activities. A survey of 1,000 patients who rated their UC symptoms on a scale of 1 to 5, with 5 being very severe, showed that patients with more severe disease reported greater disability, significantly more days missed from work and significantly more days of reduced productivity, compared with patients with less severe disease (P < 0.01). In fact, 19 percent of patients with the most severe disease were on long- or short-term medical leave from work, compared with less than seven percent of patients whose disease was less severe (P < 0.01). Of patients who were employed, those with the most severe disease missed an average of 19 days of work in the past year, compared with one day for those with the mildest disease (P < 0.01). Furthermore, even when at work, patients who rated their disease as more severe reported being less productive on more than 30 days in the past year, underscoring the negative impact of UC on patients' ability to function in the workplace.

"Many patients with ulcerative colitis report experiencing extremely bothersome symptoms, that affect many areas of their lives, including their ability to maintain full-time employment and make and keep social engagements," said Richard J. Geswell, President, Crohn's & Colitis Foundation of America. "Since patients with more severe symptoms experience more difficulties than those with milder disease, a treatment that rapidly reduces UC symptoms and keeps disease activity at bay over time may reduce the impact of the disease on patients' work status and productivity."

About the ACT Long-Term Extension

Patients with moderate to severe UC, defined as a baseline Mayo score greater than or equal to 6 and less than or equal to 12, who were unresponsive to or intolerant to at least one standard therapy, in cluding corticosteroids, immunosuppressants or 5ASAs, were enrolled in ACT 1 (n=364) or ACT 2 (n=364). The 728 patients were randomized to receive REMICADE 5 mg/kg, REMICADE 10 mg/kg or placebo at weeks 0, 2, 6 and every subsequent 8 weeks through week 22 (ACT 2) or week 46 (ACT 1). Patients were allowed to continue to receive conventional therapy.

Patients who had benefited from treatment with REMICADE and, in the investigators opinion, could enroll in the extension trials; 118 patients entered the ACT 1 extension and 111 patients entered the ACT 2 extension. During the extension, patients continued to receive REMICADE 5 mg/kg or REMICADE 10 mg/kg every 8 weeks. Patients in the extension trials were assessed using the PGA, which is 1 of 4 measures of disease activity included in the Mayo score. Of these 229 patients who entered the extension, 181 have been followed through one year, and 92 have completed two years. Patients who had responded to placebo also enrolled in the extension to maintain the blind and continued to receive placebo every 8 weeks, but were discontinued upon unblinding.

Over the course of the extension trials subjects were allowed to adjust corticosteroid use as required. When corticosteroid use during the extension in all participants (which included subjects previously on corticosteroids and those that had not used corticosteroids) was examined, a smaller proportion of the subjects who had completed follow-up through Weeks 56 and 104 were using corticosteroids. At weeks 8, 56 and 104 of the ACT extension trials, 80 percent, 88 percent and 98 percent of patients, respectively, were corticosteroid-free.

Overall, side effects were generally well tolerated with less than five percent of patients discontinuing therapy due to an adverse event (AE). As previously reported, other notable serious adverse events (SAEs) included: prostate cancer, breast cancer, pneumonia, sarcoidosis, abscess and a death following Histoplasmosis pneu monia (See Important Safety Information below.)

About the Survey

The survey findings were determined through telephone research conducted with 1,000 people with UC. Survey respondents were identified through an opt- in database of more than 17 million United States consumers who requested health information based on their condition profile, of which 40,000 self- reported having UC. Of these 40,000 potential respondents, approximately 19,000 had confirmable contact information. Contact was attempted with 7,900 with a response rate of 13 percent or a total of 1,000 patients. The survey consisted of an interview lasting about 27 minutes, and information was gathered regarding disease severity and employment characteristics.

About Ulcerative Colitis

UC, a chronic inflammatory bowel disease affecting nearly 500,000 people in the U.S., is marked by the inflammation and ulceration of the colonic mucosa, or innermost lining, which causes bloody stools, severe diarrhea and frequent abdominal pain. Tiny open sores, or ulcers, form on the surface of the lining where they bleed and produce pus and mucus. Because the inflammation makes the colon empty frequently, symptoms often lead to unwanted weight loss, blood loss and a host of secondary complications. UC is a chronic disease, and there is no cure. Although progress has been made in IBD research, investigators do not know what causes this disease.


REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and is the only anti-TNF-alpha treatment approved in three different therapeutic areas: gastroenterology, rheumatology and dermatology. REMICADE has demonstrated broad clinical utility in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in clinical trials over the past 14 years and with more than 843,000 patients treated worldwide through commercial experience.

In the U.S., REMICADE, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active RA. REMICADE is the only biologic indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active CD who have had an inadequate response to conventional therapy. REMICADE is also indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD. In December 2004, REMICADE was approved for reducing signs and symptoms in patients with active AS. In May 2005, REMICADE was approved for reducing signs and symptoms of active arthritis in patients with PsA. Additionally, in September 2005, REMICADE was approved for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy. This approval makes REMICADE the first and only biologic approved for the treatment of moderate to severe UC. In addition, on May 19, 2006, REMICADE was approved for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. This approval establishes REMICADE as the first and only biologic therapy approved for the treatment of PCD. In August 2006, REMICADE received the expanded indication for inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis. In September 2006, REMICADE was approved for t he treatment of adult patients with chronic severe plaque psoriasis. In October 2006, REMICADE was approved for maintaining clinical remission and mucosal healing in patients with moderately to severely active UC, who have had an inadequate response to conventional therapy.

REMICADE is unique among available anti-TNF biologic therapies. Unlike self-administered therapies that require patients to inject themselves frequently, REMICADE is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. In RA (3 mg/kg), CD (5 mg/kg), PsA (5 mg/kg), UC (5 mg/kg), PCD (5 mg/kg), and PsO (5 mg/kg), REMICADE is a two-hour infusion administered every 8 weeks, following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE patients may require as few as six treatments each year. In AS (5 mg/kg), REMICADE is a two-hour infusion administered every 6 weeks, following a standard induction regimen that requires treatment at weeks 0, 2 and 6.

Important Safety Information

There are reports of serious infections, including tuberculosis (TB), sepsis and pneumonia. Some of these infections have been fatal. Tell your doctor if you have had recent or past exposure to people with TB. Your doctor will evaluate you for TB and perform a TB test. If you have latent (inactive) TB, your doctor should begin TB treatment before you start REMICADE. REMICADE can lower your ability to fight infections, so if you are prone to or have a history of infections, or develop any signs of an infection such as fever, fatigue, cough, flu or warm, red or painful skin while taking REMICADE, tell your doctor right away. Also, tell your doctor if you are scheduled to receive a vaccine or if you have lived in a region where histoplasmosis or coccidioidomycosis is common.

Reports of a type of blood cancer called lymphoma in patients on REMICADE or other TNF blockers are rare but occur more often than expected for p eople in general. People who have been treated for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis for a long time, particularly those with highly active disease may be more prone to develop lymphoma. Cancers, other than lymphoma, have also been reported. Children and young adults who have been treated for Crohn's disease with REMICADE have developed a rare type of lymphoma that often results in death. These patients also were receiving drugs known as azathioprine or 6-mercaptopurine. If you take REMICADE or other TNF blockers, your risk for developing lymphoma or other cancers may increase. You should also tell your doctor if you have had or develop lymphoma or other cancers or if you have a lung disease called chronic obstructive pulmonary disease (COPD).

Many people with heart failure should not take REMICADE; so prior to treatment you should discuss any heart condition with your doctor. Tell your doctor right away if you develop new or worsening symptoms of heart failure (such as shortness of breath, swelling of your ankles or feet, or sudden weight gain).

Reactivation of hepatitis B virus has been reported in patients who are carriers of this virus and are taking TNF blockers, such as REMICADE. Some of these cases have been fatal. Tell your doctor if you know or think you may be a carrier of hepatitis B virus or if you experience signs of hepatitis B infection, such as feeling unwell, poor appetite, tiredness, fever, skin rash and/or joint pain.

There have been rare cases of serious liver injury in people taking REMICADE, some fatal. Tell your doctor if you have liver problems and contact your doctor immediately if you develop symptoms such as jaundice (yellow skin and eyes), dark brown urine, right-sided abdominal pain, fever, or severe fatigue.

Blood disorders have been reported, some fatal. Tell your doctor if you develop possible signs of blood disorders such as persistent f ever, bruising, bleeding, or paleness while taking REMICADE. Nervous system disorders have also been reported. Tell your doctor if you have or have had a disease that affects the nervous system, or if you experience any numbness, weakness, tingling, visual disturbances or seizures while taking REMICADE.

Allergic reactions, some severe, have been reported during or after infusions with REMICADE. Signs of an allergic reaction include hives, difficulty breathing, chest pain, high or low blood pressure, swelling of face and hands, and fever or chills. Tell your doctor if you have experienced a severe allergic reaction. The most common side effects of REMICADE are: respiratory infections, such as sinus infections and sore throat, headache, rash, coughing, and stomach pain.

Please read the Medication Guide for REMICADE and discuss it with your doctor.

About Centocor

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor, Inc. is a wholly owned subsidiary of Johnson & Johnson.

About Digestive Disease Week

DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 19-24, 2007, at the Washington Convention Center, Washington, DC. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit

CONTACT: Melissa Katz of Centocor, Inc., +1-215-325-6875, mobile,+1-215-514-0957

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
3. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
4. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
5. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
6. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
7. UCB Presents Long-Term CImzia Data in Crohns Disease
8. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
11. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
Post Your Comments:
(Date:10/9/2015)... Oct. 9, 2015   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... Phase 3 clinical study of telotristat etiprate has been accepted ... symposium to be held from October 15-17, in ... patients who completed the randomized treatment portion of the TELESTAR ... poster session. --> --> ...
(Date:10/9/2015)... 9, 2015 AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ... the annual European Society of Emergency Medicine (EuSEM) meeting to ... , 2015 at the Lingotto Congress Centre in ... meeting of emergency medicine practitioners in the world with over ... Data from the previously announced phase 2 bunionectomy trial will ...
(Date:10/9/2015)... -- Ansun BioPharma announced a presentation at IDSA,s IDWeek ... the compassionate use of DAS181 under an emergency IND ... co-infected with influenza and parainfluenza (Abstract # 766 , ... requirement was reduced and the patient,s respiratory status ... the respirator on day 5. Between day 2 and ...
Breaking Medicine Technology:
... PXS; Nasdaq: PXSL) today announced the appointment of ... with access to Bronchitol,through a Named Patient Program., ... unable to participate in,current Pharmaxis clinical trials but ... from a clinical condition for which no satisfactory,authorised ...
... SEATTLE, June 16 Trubion Pharmaceuticals Inc.,(Nasdaq: ... data at the 2008 Annual,European Congress of ... with TRU-015, Trubion,s lead candidate for the,treatment ... persistent,responses on the American College of Rheumatology ...
Cached Medicine Technology:
(Date:10/10/2015)... , ... October 10, 2015 , ... Story Chaser ... read. It works by reading various classics and inspiring stories and as words drop ... , The animations are extremely aesthetic and can be interacted with, making it ...
(Date:10/9/2015)... Fresno, CA (PRWEB) , ... October 09, 2015 , ... ... Interventional Pain Medical Group in Fresno , to provide highly needed medical care to ... a complete team of medical providers to diagnose, document and treat the variety of ...
(Date:10/9/2015)... ... ... A new health tool that helps identify if a sore throat is serious, ... just in time for the cold and flu season, which the Center for Disease ... U.S., the real start of cold/flu season is the start of the school year, ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... Head Over ... for the elite developmental camp at the Karolyi Ranch in Huntsville, Texas on October ... Stone, Head Over Heels girls team head coach and executive director, said. “It's a ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... and the surrounding communities, is initiating a combined charity effort with Animal Rescue ... animals in southern Louisiana. , Animal Rescue New Orleans is a non-profit ...
Breaking Medicine News(10 mins):
... state man had underlying health problems, officials say , , ... in his 30s from Snohomish County, Wash., is the third ... state health officials said late Saturday. , In a Department ... an underlying heart condition, died last week with what appear ...
... the Nancy Davis Foundation for Multiple Sclerosis LOS ANGELES, ... world,s most exclusive super sport cars, donated the proceeds ... support the Nancy Davis Foundation for Multiple Sclerosis (MS) ... event at the Hyatt Regency Century Plaza in Los ...
... alcohol are more likely to choose quick rewards , , ... a risk factor for alcoholism, a new study finds. ... bred to crave large amounts of alcohol were more ... The rodents, impulsivity was tested by giving them the ...
... experts say , , SATURDAY, May 9 (HealthDay News) -- People,s ... dissolving under a blistering acid attack that they,ve brought on ... loss of the protective enamel on teeth -- is reportedly ... when enamel is worn away by acids in the mouth, ...
... a research nurse from Thailand as a Scientology Volunteer Minister . ... natural disaster relief and medical emergency response. , ... New York City, ... of New York to train new Scientology Volunteer Ministers . But ...
... Rate through June 30, 2009PLYMOUTH MEETING, Pa., May 8 ... almost upon us, adult children everywhere are struggling to ... Health Proponent, the consumer division of Health Advocate, Inc., ... Why not give parents the gift of health ...
Cached Medicine News:
... Bard Brachytherapy loaders allow for ... and SourceLink™ Connectors to your customized ... advantage of Bard loaders is the ... "real-time" loading flexibility of the patented ...
... Every Bard BrachyStar® Needle is designed to ... efficient and clinically effective brachytherapy procedure. All ... ultra-sharp tips and polished surfaces for smooth ... needle configurations and sizes assures an ideal ...
... The BrachySource iodine-125 implant is a ... and remarkable visibility that makes BrachySource I-125 ... patients. You can be confident that every ... our seed management services which is required ...
... iodine-125 implant is a combination of innovative ... that makes BrachySource I-125 implant an ideal ... be confident that every BrachySource I-125 implant ... services which is required by clinicians who ...
Medicine Products: